The Ethical, Legal, and Social Implications (ELSI) framework was created to anticipate the broader consequences of scientific advances and to ensure that new technologies align with public interest. It addresses challenges including patient protection, fair access, environmental impact, and the creation of an effective governance. As biomedical innovation accelerated, integrating ELSI perspectives in the industry has become essential for guiding responsible research and application models.

In our innovation, we investigated the use of the green microalgae Chlamydomonas reinhardtii as a living platform for the biohybrid microbots. The system was engineered by modifying algal surfaces to promote selective interactions, while propulsion combined natural motility with magnetic guidance for enhanced control. Experimental trials showed strong target capture, greater precision in delivery, and reduced off-target deposition compared with standard carriers. Computational modeling further indicated the potential to decrease systemic exposure and associated toxicity, suggesting applications in targeted therapy, infection control, and diagnostic monitoring.

This approach will further demonstrate how biologically driven microbots can merge efficiency, sustainability, and compatibility with human health. Equally important, it underscores the need to embed ELSI considerations from the outset, ensuring that emerging microrobotic therapies are developed safely, distributed equitably, and implemented in ways that maintain societal trust.